

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (CD-167) EFIZONERIMOD ALFA
 PRONUNCIATION ef'' i zoe ner' i mod al' fa
 THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G4 [10-proline] (human heavy chain Fc fragment) fusion protein with tumor necrosis factor receptor-associated factor TRAF2 (human C-C domain fragment) fusion protein with CD252 antigen (human extracellular domain fragment), hexamer
2. Modified human immunoglobulin G4 Fc fragment (1-229) [*Homo sapiens* IGHG4*01 del-CH1, [10-proline (S>P)]Hinge] fusion protein with human TNF receptor-associated factor 2-(310-349)-peptide (230-269) fusion protein with des-(1-50)-human tumor necrosis factor ligand superfamily member 4 (CD252 antigen) (270-402), glycosylated, produced in CHO cells, hexamer

STRUCTURAL FORMULA

Monomer sequence

ESKYGPCPP	CPAPEFLGGP	SVFLFPPKPK	DTLMISRTPE	VTCVVVDVSQ	50
EDPEVQFNWY	VDGVEVHNAK	TKPREEQFN <u>S</u>	TYRVVSVLTV	LHQDWLNGKE	100
YKCKVSNKGL	PSSIEKTISK	AKGQPREPQV	YTLPPSQEEM	TKNQVSLTCL	150
VKGFYPSDIA	VEWESNGQPE	NNYKTPPVL	DSDGSFFLYS	RLTVDKSRWQ	200
EGNVFSCSVM	HEALHNHYTQ	KSLSL <u>SLGKD</u>	QDKIEALSSK	VQQLERSIGL	250
KDLAMADLEQ	KVLEME <u>EA</u> STQ	VSHRYPRIQS	IKVQFTEYKK	EKGFILTSQK	300
EDEIMKVQ <u>Q</u> NN	SVIINCDGFY	LISLKGYFSQ	EV <u>N</u> ISLHYQK	DEEPLFQLKK	350
VRSVNSLMVA	SLTYKDKVYL	<u>N</u> VTTD <u>N</u> TSLD	DFHVNGGELI	LIHQNPGEFC	400
VL					402

Disulfide bridges location

8-8'	11-11'	43-103	149-207	316-400
------	--------	--------	---------	---------

Glycosylation sites (N)

Asn-79 Asn-309 Asn-333 Asn-371 Asn-376

MOLECULAR FORMULA $C_{2037}H_{3184}N_{532}O_{626}S_{15}$ (peptide monomer)

MOLECULAR WEIGHT 300 kDa (glycosylated hexamer)

TRADEMARK None as yet

SPONSOR MedImmune

CODE DESIGNATIONS	MEDI6383
<u>CAS</u> REGISTRY NUMBER	1635395-27-5
UNII	1MH7C2X8KE
WHO NUMBER	10417

NOTE: This adoption statement N17/49 for *efizonerimod alfa* replaces the adoption statement N16/109 for *efizonerimod*. The adoption statement N16/109 is hereby rescinded.

SCS